A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome

BACKGROUND: Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity to zoledronic acid > 200-fold, determined by the half-maximal inhibitory conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Qihua, Møller, Anaïs Marie Julie, Qiu, Chuan, Madsen, Jonna Skov, Shen, Hui, Bechmann, Troels, Delaisse, Jean-Marie, Kristensen, Bjarne Winther, Deng, Hong-Wen, Karasik, David, Søe, Kent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012449/
https://www.ncbi.nlm.nih.gov/pubmed/36915112
http://dx.doi.org/10.1186/s13148-023-01449-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012449/
https://www.ncbi.nlm.nih.gov/pubmed/36915112
http://dx.doi.org/10.1186/s13148-023-01449-1

Ejemplares similares